Resilience

Executive Summary

Resilience is a private biomanufacturing CDMO founded in 2020, headquartered in San Diego, California. The company offers end-to-end development and manufacturing services for complex medicines, including biologics, cell therapies, and gene therapies. Its mission is to improve access to these treatments and protect biopharmaceutical supply chains through a network of North American facilities that provide drug substance and drug product manufacturing, aseptic fill/finish, and packaging. Since its inception, Resilience has focused on building a robust, agile manufacturing platform to address industry challenges such as supply chain vulnerabilities and capacity constraints. As a relatively new entrant in the CDMO space, the company aims to differentiate itself through technological innovation and a patient-centric approach. Resilience's strategic emphasis on emerging modalities like cell and gene therapy positions it well in a high-growth market segment. However, as a private entity, detailed financial and operational metrics are not publicly available, making it difficult to assess its current market position and performance. The company's success will depend on its ability to secure long-term partnerships, expand its facility capacity, and achieve regulatory approvals for its manufacturing processes.

Upcoming Catalysts (preview)

• Q3 2026Announcement of major partnership with a biopharmaceutical company for cell/gene therapy manufacturing65% success
• Q2 2027Completion and FDA approval of a new aseptic fill/finish facility in North America50% success
• Q4 2026Series C or later funding round to support expansion, with disclosed valuation40% success